Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297248 | 0.86 | HDAC1 (0.47) | MEN1KMT2AMAPTHDAC1GLA | |
| SCHEMBL23297330 | 0.84 | MEN1 (0.60) | MEN1KMT2AMAPTCYP1A2CYP2D6 | |
| SCHEMBL23334351 | 0.80 | HDAC1 (0.45) | MEN1KMT2AMAPTMAPK1HDAC1 | |
| SCHEMBL23334448 | 0.80 | HDAC1 (0.47) | MEN1KMT2AMAPTHDAC1GLA | |
| SCHEMBL23334066 | 0.79 | HDAC1 (0.46) | MEN1KMT2AMAPTCYP2C9HDAC1 | |
| SCHEMBL23297188 | 0.78 | HDAC1 (0.51) | MEN1KMT2AMAPTCYP2C9HDAC1 | |
| SCHEMBL23297284 | 0.77 | MEN1 (0.60) | MEN1KMT2AMAPTCYP2C9HDAC1 | |
| SCHEMBL26627749 | 0.77 | HDAC1 (0.45) | MEN1KMT2AMAPTHDAC1GLA | |
| SCHEMBL26627126 | 0.76 | MEN1 (0.50) | MEN1KMT2AMAPTPOLBTP53 | |
| SCHEMBL23297349 | 0.74 | MEN1 (0.72) | MEN1KMT2AMAPTHDAC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240833-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3877367-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2021231630-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MEN1 4467/4885KMT2A 3767/4885MAPT 1863/4885 |
| US-12240833-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885 |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885 |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885 |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.